---
title: "Kuo Fu-Feng Discloses Investment at Jyong Biotech with 33.34% Stake"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284046753.md"
description: "Ms. Kuo Fu-Feng disclosed a 33.34% stake in Jyong Biotech Ltd. through a Schedule 13D filing, dated April 24, 2026. As CEO and Chairwoman, she holds significant influence but states the shares are for investment purposes without plans for mergers or governance changes. Kuo exercises sole voting power over 25,349,500 shares held by Perfect Minds Co., Ltd. and does not set ownership caps or timelines for future actions. Her investment reflects a strategic, long-term approach in the company she leads."
datetime: "2026-04-24T19:16:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284046753.md)
  - [en](https://longbridge.com/en/news/284046753.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284046753.md)
generator: "portal-rs"
---

# Kuo Fu-Feng Discloses Investment at Jyong Biotech with 33.34% Stake

Ms. Kuo Fu-Feng disclosed a 33.34% stake in Jyong Biotech Ltd. through a Schedule 13D filing. The filing, dated April 24, 2026, details ownership through Perfect Minds Co., Ltd. and related trust entities. The position gives Kuo meaningful influence, as she also serves as Jyong Biotech’s CEO and Chairwoman.

**Investor Intent**

Kuo states she holds the shares for investment purposes and does not outline plans for actions like mergers, board changes, buybacks, or asset sales. The filing makes no commitments to specific strategic or governance moves at this time.

She exercises sole voting and dispositive power over the 25,349,500 shares held by Perfect Minds Co., Ltd., but she does not set any ownership caps or timelines for future actions. The group also disclaims that it forms a Section 13(d) “group,” except as expressly stated.

**Investor's Background**

Ms. Kuo Fu-Feng is the Chief Executive Officer and Chairwoman of Jyong Biotech Ltd. She is the settlor of The Innovation Trust and the sole director of Perfect Minds Co., Ltd., which directly holds the reported shares. Her investment approach here centers on a strategic, long-term stake in the company she leads.

Original SEC Filing: Jyong Biotech Ltd. \[ MENS \] - SCHEDULE 13D - Apr. 24, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [MENS.US](https://longbridge.com/en/quote/MENS.US.md)

## Related News & Research

- [Time to Nibble on MCD Stock After it Enters Oversold Territory?](https://longbridge.com/en/news/300812314.md)
- [Cathie Wood Is Buying Rocket Lab Again: Why 3 ARK ETFs Are Betting on Neutron](https://longbridge.com/en/news/300816393.md)
- [ARK's Winton says each Starship launch could add $700 million a year](https://longbridge.com/en/news/300832406.md)
- [Seagate vs. Western Digital: One Stock Is a Buy After Today's Drop, but the Other Has More Upside, According to Goldman Sachs](https://longbridge.com/en/news/300813818.md)
- [‘Watch That Cliff,’ Says Top Investor on Micron Stock](https://longbridge.com/en/news/300813618.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**